全文获取类型
收费全文 | 42724篇 |
免费 | 3401篇 |
国内免费 | 565篇 |
专业分类
耳鼻咽喉 | 523篇 |
儿科学 | 1075篇 |
妇产科学 | 919篇 |
基础医学 | 5550篇 |
口腔科学 | 670篇 |
临床医学 | 4466篇 |
内科学 | 8779篇 |
皮肤病学 | 707篇 |
神经病学 | 3625篇 |
特种医学 | 1777篇 |
外国民族医学 | 3篇 |
外科学 | 6640篇 |
综合类 | 1418篇 |
现状与发展 | 1篇 |
一般理论 | 53篇 |
预防医学 | 3014篇 |
眼科学 | 852篇 |
药学 | 2719篇 |
4篇 | |
中国医学 | 372篇 |
肿瘤学 | 3523篇 |
出版年
2023年 | 476篇 |
2022年 | 954篇 |
2021年 | 1857篇 |
2020年 | 992篇 |
2019年 | 1410篇 |
2018年 | 1601篇 |
2017年 | 1187篇 |
2016年 | 1174篇 |
2015年 | 1492篇 |
2014年 | 1939篇 |
2013年 | 2268篇 |
2012年 | 3460篇 |
2011年 | 3460篇 |
2010年 | 1939篇 |
2009年 | 1556篇 |
2008年 | 2359篇 |
2007年 | 2401篇 |
2006年 | 2177篇 |
2005年 | 2012篇 |
2004年 | 1749篇 |
2003年 | 1487篇 |
2002年 | 1274篇 |
2001年 | 637篇 |
2000年 | 547篇 |
1999年 | 566篇 |
1998年 | 307篇 |
1997年 | 282篇 |
1996年 | 315篇 |
1995年 | 261篇 |
1994年 | 189篇 |
1993年 | 172篇 |
1992年 | 310篇 |
1991年 | 298篇 |
1990年 | 269篇 |
1989年 | 254篇 |
1988年 | 229篇 |
1987年 | 205篇 |
1986年 | 197篇 |
1985年 | 199篇 |
1984年 | 176篇 |
1983年 | 154篇 |
1982年 | 153篇 |
1981年 | 135篇 |
1980年 | 113篇 |
1979年 | 142篇 |
1978年 | 136篇 |
1977年 | 79篇 |
1975年 | 68篇 |
1974年 | 87篇 |
1973年 | 67篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
111.
Arthroscopic shoulder surgery has become a safe tool for evaluation and treatment of a wide range of shoulder problems with few complications. With ever-improving technology (and commitment to motor skill development among arthroscopists), we can expect to maintain this low rate despite increasing procedure complexity. Avoiding complications in arthroscopic shoulder surgery requires careful preoperative planning, judicious patient selection, a thorough understanding of arthroscopic anatomy, and facility with arthroscopic techniques. 相似文献
112.
Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials.
Vincent Meininger Gilbert Bensimon Walter R Bradley Benjamin Brooks Patrice Douillet Andrew A Eisen Lucette Lacomblez P Nigel Leigh Wim Robberecht 《Amyotrophic lateral sclerosis and other motor neuron disorders》2004,5(2):107-117
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal motor neuron disease. We carried out two randomized, double-blind, placebo-controlled, multi-centre, multi-national studies with xaliproden (a drug with neurotrophic effect) to assess drug efficacy and safety at two doses. Patients with clinically probable or definite ALS of more than 6 months and less than 5 years duration were randomly assigned to placebo, 1 mg or 2 mg xaliproden orally once daily as monotherapy in Study 1 (n=867); or to the same regimen with addition of riluzole 50 mg bid background therapy in Study 2 (n=1210 patients). The two primary endpoints were defined as: 1. Time to death, tracheostomy, or permanent assisted ventilation (DTP), and 2. Time to vital capacity (VC)<50% or DTP before (log-rank test) and after adjustment using a Cox proportional hazard model for prespecified prognostic factors. Secondary endpoints were rates of change of various functional measures. In Study 1, primary outcome measures did not reach statistical significance. For the 2 mg group, for time to VC<50% analysis (without DTP) a significant 30% RRR was obtained (95% confidence interval [CI]: 8.46, P=0.009). In Study 2, no significant results were obtained. However, there was a trend in favour of add-on 1 mg dose xaliproden vs. placebo (RRR 15% [-6.31, ns] for time to VC<50%; RRR 12% [CI: -6.27, ns] for time to VC<50% or DTP). Adjusted RR ratios were consistently more favourable for the xaliproden groups. Tolerability was good, and dose-dependent side effects were largely associated with the serotonergic properties of xaliproden. An effect of xaliproden on functional parameters, especially VC, was noted. Although this effect did not reach statistical significance, xaliproden had a small effect on clinically noteworthy aspects of disease progression in ALS. 相似文献
113.
114.
C E Chu A Cooke J B Stephenson J L Tolmie B Clarke W L Parry-Jones J M Connor M D Donaldson 《Archives of disease in childhood》1994,71(5):441-442
Thirty one patients with the putative diagnosis of Prader-Willi syndrome were reassessed clinically and by DNA analysis. Eleven patients were judged not to have Prader-Willi syndrome and 20 to have the condition. This was confirmed by DNA analysis in all but one case. The diagnosis of Prader-Willi syndrome, especially in early infancy, should be made with caution unless confirmed by molecular genetic studies. 相似文献
115.
There is a great deal of indirect, nonexperimental evidence that a pattern of earlier-stage disease at diagnosis has a better outcome. Increased early detection activities can change, these stage patterns while various biases and the question of generalizability need to be kept in mind in their interpretation. The indirect evidences of possible benefit from early detection activities includes an increase in the number of cases detected, a pattern of more early- and less advanced-stage cases, an increase in the overall site-specific survival rate, and a decrease in the case fatality rate. Unless these intermediate markers are favorable, it is unlikely that early detection will reduce mortality. In addition, one should also differentiate a reduced incidence or a change in treatment as a cause for reduced mortality. 相似文献
116.
L S Benjamin 《Dental clinics of North America》1992,36(1):77-93; discussion 94-5
The subperiosteal implant has long been regarded as the most successful, predictable, and versatile of all implant systems. In some cases, however, anatomic morphology and surgical technique present certain limitations for the subperiosteal procedure. Through CAD/CAM multiplanar diagnostic imaging, not only have we been able to eliminate the first stage of the surgical procedure, but we have expanded the capabilities and versatility of the subperiosteal procedure. In addition, coating the subperiosteal implant frame with hydroxyapatite has allowed the achievement of bony union, thus increasing the long-range prognosis of the individual case. 相似文献
117.
The role of various subfamilies of rat hepatic cytochrome P450 in the oxidation of ethosuximide was evaluated by comparing ethosuximide clearance in control rats and those pretreated with relatively selective P450 inducers and/or inhibitors. Clotrimazole pretreatment increased ethosuximide clearance threefold (p less than 0.005). Dexamethasone increased ethosuximide clearance twofold (p less than 0.001), and the dexamethasone effect was completely abolished by a single dose of triacetyloleandomycin. These results suggest a prominent role for cytochrome P450IIIA in ethosuximide metabolism in the rat. Isoniazid increased ethosuximide clearance twofold (p less than 0.001), and this effect was abolished by a single dose of diallylsulfide, suggesting that ethosuximide is also processed by cytochrome P450IIE1 in rats. Phenobarbital pretreatment increased ethosuximide clearance 2-2.7 fold (p less than 0.001); an effect that was only partially reversed by orphenadrine, an inhibitor of cytochrome P450IIB/IIC enzymes. This suggests a quantitatively less important role for the IIB/IIC subfamilies in processing ethosuximide, since phenobarbital is an inducer of P450 subfamilies IIB, IIC, IIE, and IIIA. Neither the cytochrome P450IA inducer, beta-naphthoflavone, nor the inhibitor, alpha-naphthoflavone altered ethosuximide clearance. Ajmaline, an inhibitor of cytochrome P450IID, had no effect on ethosuximide clearance. Together, these findings suggest that ethosuximide is principally oxidized by cytochrome P450IIIA, and that cytochrome P450IIE may play an important role. Cytochromes P450IIB/C play less prominent roles in ethosuximide oxidation, and neither cytochrome P450IA nor cytochrome P450IID is involved. 相似文献
118.
I Chu D C Villeneuve V E Secours R Otson V E Valli 《Journal of toxicology and environmental health》1991,33(3):317-326
The present study was conducted to determine the dermal toxicity of coal coprocessing products and to assess their potential health hazards. Groups of 10 male and 10 female Sprague-Dawley rats were administered dermally coal coprocessing products (light gas oil, LGO; heavy gas oil I, HGOI; heavy gas oil II, HGOII) at 1 g/kg body weight/d for 14 d. The control and positive control groups received normal saline and a coal liquefaction product (CLP) at the same dose level, respectively. Treatment with either the three fractions of coprocessing products or CLP caused decreased growth rate and food consumption in animals of both sexes. Liver enlargement occurred in groups treated with HGOI, HGOII, and CLP. Decreased serum glucose was observed in animals of both sexes treated with the three fractions and CLP. Treatment with HGOI and CLP caused an elevation of hepatic microsomal ethoxyresorufin deethylase activity in the rat of both sexes. The three fractions and CLP caused mild anemia. Mild treatment-related histological changes were observed in the liver, spleen, thyroid, bone marrow, and kidney. All three fractions of coprocessing products were tested for their mutagenicity in five strains of Salmonella typhimurium: TA98, TA100, TA1535, TA1537, and TA1538. HGOI, after metabolic activation, was found to be mutagenic in the strains of TA98, TA100, and TA1538. In contrast, HGOII was mutagenic in the five strains with or without metabolic activation. These data indicate that HGOI and HGOII are more toxic than LGO, and should be subjected to further studies to determine their long-term effects. 相似文献
119.
120.
Shlomo Kyzer M.D. Benjamin Mitmaker M.D. Ph.D. F.R.C.S. Philip H. Gordon M.D. F.R.C.S. F.A.C.S. Hyman Schipper M.D. Ph.D. F.R.C.P. Eugenia Wang Ph.D. 《Diseases of the colon and rectum》1992,35(9):879-883
The field change is one hypothesis concerning the development of colorectal carcinoma. Removal of a carcinoma without its entire surrounding altered mucosa may result in the development of a recurrence. S44, a monoclonal antibody directed against statin, a nuclear protein expressed in nonproliferating cells in either a quiescent or senescent state, was used to determine the rate of cell growth in colorectal mucosa at different distances from carcinomas. The specimens of 18 patients undergoing resection of a colorectal carcinoma were immediately opened after operation, and strips of mucosa were taken at distances of 1 cm, 5 cm, and 10 cm from the carcinoma. For each location, 10 longitudinally oriented crypts were evaluated for statin-positive cells identified by the presence of a dark brown peroxidase-conjugated antibody reaction product. The average percentage of statin-positive cells per crypt was significantly lower at a 1-cm distance from the carcinoma compared with the mucosa located 5 and 10 cm from the carcinoma (20.89±4.33 at 1 cm, 32.41±5.27 at 5 cm, and 34.23±6.45 at 10 cm). None of the calculated parameters showed any significant difference between the 5-cm and 10-cm locations. The fact that the proliferation rate of the mucosal cells returns to the normal level at 5 cm from the margin of the carcinoma suggests that cells located within this distance still retain proliferative potential even though they are morphologically indistinguishable from their normal counterparts. We conclude that failure to remove this transitional, potentially proliferative mucosa may result in subsequent development of anastomotic or perianastomotic recurrences.This study was conducted with support from the Sir Mortimer B. Davis-Jewish General Hospital Foundation and the American Physician Fellowship and with grants to Eugenia Wang from the Medical Research Council of Canada and from the National Institute on Aging of the National Institutes of Health of the U.S.A. 相似文献